Evaxion to announce business update and third quarter 2024 financial results on October 31

$EVAX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $EVAX alert in real time by email

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. 



Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. 



To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.  



To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event. 



Contact information  

Evaxion Biotech A/S

Mads Kronborg

Vice President, Investor Relations & Communication

+45 53 54 82 96  

mak@evaxion-biotech.com  



About EVAXION  

Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients' lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website



Forward-looking statement  

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate," "continue," "estimate," "plan," "potential," "predict," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.  



Primary Logo

Get the next $EVAX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • When will Evaxion Biotech report its third quarter 2024 financial results?

    Evaxion Biotech A/S will release its third quarter financial results on October 31, 2024, before the market opens.

  • What time is the conference call scheduled for Evaxion's business update?

    The conference call will take place at 13:30 CET / 08:30 EST on the same day as the financial results are released.

  • How can participants join the conference call?

    Interested participants must register in advance to receive dial-in information and a unique PIN code for the conference call.

  • What is Evaxion Biotech's area of expertise?

    Evaxion Biotech specializes in developing AI-powered vaccines for cancer, bacterial diseases, and viral infections using its AI-Immunology™ platform.

  • Will a recording of the conference call be available for those who cannot attend live?

    The webcast recording will be available shortly after the event on Evaxion's website.

Recent Analyst Ratings for
$EVAX

DatePrice TargetRatingAnalyst
4/2/2024$8.00Neutral → Buy
Ladenburg Thalmann
2/12/2024$14.00Buy
H.C. Wainwright
More analyst ratings

$EVAX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

    COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

    New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting These data will further add to the already strong clinical data package for EVX-01The trial remains on track for two-year clinical efficacy data readout in the second half of 2025COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. D

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to present at numerous upcoming conferences

    Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting at several investor and scientific conferences in March and throughout the second quarter of 2025. Evaxion will be providing company and scientific updates as well as engaging with different stakeholders at conferences in both the US and Europe. As such, conference participation is an important part of our strategy to identify potential partners and opportunities for both

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EVAX
SEC Filings

See more

$EVAX
Leadership Updates

Live Leadership Updates

See more
  • Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

    Dr. Rønø has developed Evaxion's pre-clinical and early clinical oncology pipelineNewly-created Chief Scientific Officer role strengthens Evaxion's leadership team COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today it has promoted its Senior Director, Immuno-Oncology, Birgitte Rønø, Ph.D, to the newly-created position of Chief Scientific Officer, effective immediately. Lars Wegner, CEO of Evaxion, said: "As Senior Di

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion Biotech Appoints Lars Holtug to the Board of Directors

    COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today its shareholders elected Lars Holtug, a highly experienced financial professional with specific expertise in the healthcare industry, as a member of its Board of Directors. The vote was held at Evaxion's Annual General Meeting on May 25, 2021. Lars Holtug will also chair Evaxion's Audit Committee, taking over from Helen M. Boudreau, who chose not to stand for re-election for personal reasons. Marianne Søgaard, Chairwo

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Financials

Live finance-specific insights

See more
  • Evaxion to announce business update and full year 2024 financial results on April 1, 2025

    COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numb

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to announce business update and third quarter 2024 financial results on October 31

    COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.  Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.  To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receiv

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

    COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CEST/08:30 EDT presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance v

    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$EVAX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more